Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06652412 | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC | not yet recruiting | Phase 2 | 124 | Fudan UniversityOTHER | 0 | Oct 28, 2024 | clinicaltrials |
| NCT06656559 | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER |
| 0 |
| Oct 24, 2024 |
| clinicaltrials |
| NCT06650709 | NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study(NEOCATS) | not yet recruiting | Phase 2 | 40 | British Columbia Cancer AgencyOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06652139 | Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive | not yet recruiting | Phase 2 | 82 | Ruijin HospitalOTHER | 0 | Oct 22, 2024 | clinicaltrials |
| NCT06652685 | Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 218 | Ruijin HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | not yet recruiting | Phase 2 | 68 | Harbin Medical UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06646211 | High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06641453 | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06644313 | Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 31 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06549335 | Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL) | not yet recruiting | Phase 2 | 66 | Ruijin HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06597513 | Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC | not yet recruiting | Phase 1 / Phase 2 | 10 | Zhou ChengzhiOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06459921 | Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer | not yet recruiting | Phase 2 | 200 | Xijing HospitalOTHER | 0 | Oct 10, 2024 | clinicaltrials |
| NCT06630871 | A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. | not yet recruiting | Phase 2 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06634667 | Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06632522 | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . | not yet recruiting | Phase 2 | 46 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06631040 | Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL | not yet recruiting | Phase 1 / Phase 2 | 10 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06598384 | VA as Maintenance Therapy Post Allo-HSCT in MDS and AML | not yet recruiting | Phase 2 | 40 | Navy General Hospital, BeijingOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06618391 | Local Injection and Systemic Therapy in the Treatment of NSCLC. | not yet recruiting | Phase 2 | 84 | Henan Cancer HospitalOTHER_GOV | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06620029 | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | not yet recruiting | Phase 1 / Phase 2 | 27 | BioMimetix JV, LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06620796 | A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 70 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06620822 | Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial | not yet recruiting | Phase 2 | 296 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06621095 | Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) | not yet recruiting | Phase 2 | 104 | RenJi HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06614231 | Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06614621 | A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06611826 | GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC | not yet recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06537297 | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06497543 | Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic | not yet recruiting | Phase 2 | 80 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586866 | JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases | not yet recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06588179 | SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt | not yet recruiting | Phase 1 / Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588335 | BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Henan Provincial People's HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06592287 | The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 66 | Xianglin YuanOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592612 | Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment | not yet recruiting | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06593548 | Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer | not yet recruiting | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594432 | Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594692 | Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study(mRCAT-C) | not yet recruiting | Phase 2 | 140 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06596343 | Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 80 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06598917 | Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT | not yet recruiting | Phase 2 | 60 | China Medical University HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06598969 | TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia(TMLI-MA) | not yet recruiting | Phase 2 | 58 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599775 | Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer | not yet recruiting | Phase 2 | 42 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06599827 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC(iMHRT-LARC) | not yet recruiting | Phase 2 | 54 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06600841 | Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer | not yet recruiting | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602323 | TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.(TMLI-RI) | not yet recruiting | Phase 2 | 34 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06604351 | Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction(Example) | not yet recruiting | Phase 2 | 39 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585644 | A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC | not yet recruiting | Phase 2 | 44 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT06258018 | Niraparib and Temozolomide in Patients Glioblastoma(ONC-2022-001) | not yet recruiting | Phase 1 / Phase 2 | 86 | Armando Santoro, MDOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06577961 | Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients | not yet recruiting | Phase 1 / Phase 2 | 37 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06578286 | ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | not yet recruiting | Phase 2 | 44 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06574412 | Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma. | not yet recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT06573138 | Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL | not yet recruiting | Phase 2 | 18 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 28, 2024source: clinicaltrials